Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Aug 5:2020:2743060.
doi: 10.1155/2020/2743060. eCollection 2020.

Study on the Diagnosis of Gastric Cancer by Magnetic Beads Extraction and Mass Spectrometry

Ning Zhu #  1 , Xiaoliang Xing #  1 , Limei Cao  2 , Yingjun Zhang  1 , Ti Zhang  1 , Zhen Li  1 , Fen Zou  3 , Qing Li  1
Affiliations
Clinical Trial

Study on the Diagnosis of Gastric Cancer by Magnetic Beads Extraction and Mass Spectrometry

Ning Zhu et al. Biomed Res Int. .

Abstract

Objective: This study constructed a model for the early diagnosis of gastric cancer by comparing the serum peptides profiles of patients with advanced gastric cancer and healthy people. And that model may be the potential to be applied for the efficacy evaluation and recurrence monitoring in gastric cancer.

Methods: Serums of 30 healthy people and 30 advanced gastric cancer patients were matched by age and gender were collected. The serum peptide spectrum was obtained by MB-WCX concentration and MALDI-TOF MS analysis. Based on the analysis of the efficiency of differential peptides in the diagnosis of gastric cancer, we first established a model for the diagnosis of gastric cancer based on differential peptides and then carried out external verification. The diagnostic reliability of this model was further tested by compared with carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).

Results: In this present study, we found the expression of two peptide peaks with a molecular weight of 2863 Da and 2953 Da were significantly increased in gastric cancer serum, while the expression of two peptide peaks with a molecular weight of 1945 Da and 2082 Da were significantly decreased. Depending on the characteristics of peptide expression, we constructed a diagnostic model, we compared the sensitivity and specificity of the model established by 2953 Da/1945 Da, and found this model is significantly higher than CEA and CA19-9.

Conclusion: There were some differences in serum peptides profiles between patients with advanced gastric cancer and healthy people. The serum peptide diagnostic models based on 2953 Da and 1945 Da have high diagnostic efficiency for advanced gastric cancer. Our result indicated that this model was well worth further validation for clinical diagnosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. The authors declare no competing financial interests.

Figures

Figure 1
Figure 1
Differential analysis of serum peptides expression profile between healthy and gastric cancer patients. (a) The serum peptide expression profiles of 20 healthy patients and 20 gastric cancer patients were summarized (The horizontal coordinate is mass/charge (m/z), reflecting molecular weight. The ordinate is the sample number: red is the serum sample group of gastric cancer, green is the serum sample group of healthy people). (b) PCA plots of gastric cancer group and healthy group (Red: gastric cancer group; Green: health group). (c) Statistics of 4 differential peptide peaks (left: peptide peaks of all 40 samples; in average peak diagram of the two groups; right: Box diagram. Gastric cancer is red, healthy is green).
Figure 2
Figure 2
Establishment of serum peptides diagnostic model based on No.29 (2953 Da)/No.16 (1945 Da). (a) Diagnostic efficiency analysis of 4 differential peptide peaks (the horizontal line in the figure is the median numerical line). (b) The diagnostic effect of gastric cancer based on the ration of No.29 (2953 Da)/No.16 (1945 Da).
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Guan W. L., Yuan L. P., Yan X. L., Yang D. J., Qiu M. Z. More attention should be paid to adult gastric cancer patients younger than 35 years old: extremely poor prognosis was found. Journal of Cancer. 2019;10(2):472–478. doi: 10.7150/jca.27517. - DOI - PMC - PubMed
    1. Park J. C., Lee Y. C., Kim J. H., et al. Clinicopathological features and prognostic factors of proximal gastric carcinoma in a population with high Helicobacter pylori prevalence: a single-center, large-volume study in Korea. Annals of Surgical Oncology. 2010;17(3):829–837. doi: 10.1245/s10434-009-0785-x. - DOI - PubMed
    1. Petricoin E. F., Ardekani A. M., Hitt B. A., et al. Use of proteomic patterns in serum to identify ovarian cancer. The Lancet. 2002;359(9306):572–577. doi: 10.1016/S0140-6736(02)07746-2. - DOI - PubMed
    1. Li S., Huang M., Liu Q., et al. Serum expression of β-catenin is a potential detection marker in patients with colorectal cancer. Disease Markers. 2019;2019:8. doi: 10.1155/2019/5070524.5070524 - DOI - PMC - PubMed

Publication types

Substances